Health Economics›Breast cancer›Metastatic disease subsequent lines of chemotherapy

Metastatic disease subsequent lines of chemotherapy

Breast cancer · 29 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 23 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Paclitaxel, nanoparticle albumin-bound and Bevacizumab Variant #01	—	R 102 337	28d	6.8 mo	—	2	R 204 675 PFS proxy	2
Trastuzumab deruxtecan monotherapy Variant #01	—	R 81 019	21d	15.5 mo	23.4 mo	2	R 162 039 PFS proxy	9
Pegylated liposomal doxorubicin and Bevacizumab Variant #01	—	R 54 164	28d	6.3 mo	—	2	R 108 329 PFS proxy	1
Gemcitabine and Bevacizumab Variant #01	—	R 43 181	28d	6.8 mo	—	2	R 86 361 PFS proxy	2
Paclitaxel and Bevacizumab Variant #01	—	R 40 612	28d	7.2 mo	—	2	R 81 225 PFS proxy	1
Doxorubicin and Bevacizumab Variant #01	—	R 39 066	28d	6.3 mo	—	2	R 78 132 PFS proxy	1
Docetaxel and Bevacizumab Variant #01	—	R 32 908	21d	6.8 mo	—	9	R 296 169 PFS proxy	2
Capecitabine and Bevacizumab Variant #01	—	R 31 025	21d	6.8 mo	—	2	R 62 050 PFS proxy	4
Non-pegylated liposomal doxorubicin and Bevacizumab Variant #01 Partial	—	R 29 986	21d	6.3 mo	—	2	R 59 972 PFS proxy	1
Eribulin monotherapy Variant #01	—	R 22 427	21d	4.1 mo	13.1 mo	2	R 44 854 PFS proxy	21
Vinorelbine and Bevacizumab Variant #01	—	R 19 997	14d	7.2 mo	—	2	R 39 994 PFS proxy	1
Capecitabine and Ixabepilone Variant #01	—	R 16 543	21d	5.8 mo	16.4 mo	2	R 33 086 PFS proxy	4
nab-Paclitaxel monotherapy Variant #01	—	R 16 043	28d	5.3 mo	16.8 mo	2	R 32 087 PFS proxy	6
Ixabepilone monotherapy Variant #01	—	R 15 504	21d	—	~7.5 mo	~2	~R 31 009 PFS proxy · indirect	1
Pegylated liposomal doxorubicin monotherapy Variant #02	—	R 8 000	28d	3.6 mo	—	6	R 48 000 PFS proxy	2
Docetaxel and Gemcitabine Variant #01	—	R 6 266	21d	—	~26.9 mo	~9	~R 56 391 PFS proxy · indirect	2
Carboplatin and Gemcitabine (GCb) Variant #01	—	R 4 414	21d	4.1 mo	—	2	R 8 829 PFS proxy	1
Capecitabine and Docetaxel (TX) Variant #01	—	R 3 311	21d	9.2 mo	14.5 mo	2	R 6 622 PFS proxy	2
Docetaxel monotherapy Variant #02	—	R 2 921	28d	4.7 mo	11.4 mo	2	R 5 843 PFS proxy	5
Cisplatin and Vinorelbine (CVb) Variant #01	—	R 2 418	21d	—	~10.0 mo	~6	~R 14 510 PFS proxy · indirect	11
Cyclophosphamide monotherapy Variant #01	—	R 1 680	28d	—	9.3 mo	1	R 1 680 PFS proxy	1
Gemcitabine monotherapy Variant #01	—	R 1 672	21d	4.6 mo	11.2 mo	7	R 11 705 PFS proxy	15
Capecitabine monotherapy Variant #01	—	R 1 039	21d	4.5 mo	15.6 mo	2	R 2 077 PFS proxy	33
Doxorubicin monotherapy Variant #01	—	R 902	21d	5.1 mo	13.8 mo	9	R 8 114 PFS proxy	2
Capecitabine and Vinflunine Variant #01 Partial	—	R 857	21d	5.6 mo	—	2	R 1 714 PFS proxy	1
Paclitaxel monotherapy Variant #02	—	R 734	28d	5.4 mo	16.5 mo	7	R 5 141 PFS proxy	11
Vinorelbine monotherapy Variant #01	—	R 458	21d	4.0 mo	10.8 mo	7	R 3 203 PFS proxy	17
Cyclophosphamide and Methotrexate (CM) Variant #01	—	R 269	7d	—	—	~2	~R 538 indirect	—
Non-pegylated liposomal doxorubicin monotherapy Variant #01 Partial	—	—	21d	4.2 mo	—	2	—	1

29 of 29 regimens shown